Sociedad Americana de Hirudoterapia

Contaminated heparin and outcomes after cardiac surgery: a retrospective propensity-matched cohort study

Research article published in PloS one (2014)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosSeguridad y control de infeccionesKaiser HA et al. · PloS one, 2014

Abstract

BACKGROUND: During 2007 and 2008 it is likely that millions of patients in the US received heparin contaminated (CH) with oversulfated chondroitin sulfate, which was associated with anaphylactoid reactions. We tested the hypothesis that CH was associated with serious morbidity, mortality, intensive care unit (ICU) stay and heparin-induced thrombocytopenia following adult cardiac surgery. METHODS AND FINDINGS: We conducted a single center, retrospective, propensity-matched cohort study during the period of CH and the equivalent time frame in the three preceding or the two following years. Perioperative data were obtained from the institutional record of the Society of Thoracic Surgeons National Database, for which the data collection is prospective, standardized and performed by independent investigators. After matching, logistic regression was performed to evaluate the independent effect of CH on the composite adverse outcome (myocardial infarction, stroke, pneumonia, dialysis, cardiac arrest) and on mortality. Cox regression was used to determine the association between CH and ICU length of stay. The 1∶5 matched groups included 220 patients potentially exposed to CH and 918 controls. There were more adverse outcomes in the exposed cohort (20.9% versus 12.0%; difference  =  8.9%; 95% CI 3.6% to 15.1%, P < 0.001) with an odds ratio for CH of 2.0 (95% CI, 1.4 to 3.0, P < 0.001). In the exposed group there was a non-significant increase in mortality (5.9% versus 3.5%, difference = 2.4%; 95% CI, -0.4 to 3.5%, P  =  0.1), the median ICU stay was longer by 14.1 hours (interquartile range -26.6 to 79.8, S = 3299, P = 0.0004) with an estimated hazard ratio for CH of 1.2 (95% CI, 1.0 to 1.4, P = 0.04). There was no difference in nadir platelet counts between cohorts. CONCLUSIONS: The results from this single center study suggest the possibility that contaminated heparin might have contributed to serious morbidity following cardiac surgery.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAdolescentAdultAgedAged, 80 and overCardiac Surgical ProceduresChondroitin SulfatesDrug ContaminationFemaleHeart ArrestHeparinHumansIntensive Care Units

Resumen

During 2007 and 2008 it is likely that millions of patients in the US received heparin contaminated (CH) with oversulfated chondroitin sulfate, which was associated with anaphylactoid reactions.

Por qué esto importa para la hirudoterapia

This single-center retrospective propensity-matched cohort study investigated the clinical outcomes of 220 patients potentially exposed to heparin contaminated with oversulfated chondroitin sulfate during cardiac surgery, comparing them to 918 controls. The study found an association between contaminated heparin exposure and increased serious morbidity, including a composite of myocardial infarction, stroke, pneumonia, dialysis, and cardiac arrest, as well as longer ICU stays. The research evaluates adverse events associated with a specific period of heparin contamination and does not involve leeches, hirudotherapy, or any leech-derived compounds. Therefore, its relevance to the American Society of Hirudotherapy is absent, serving only as an analysis of risks associated with contaminated heparin.

Citación

Contaminated heparin and outcomes after cardiac surgery: a retrospective propensity-matched cohort study

Kaiser HA et al. · PloS one, 2014

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.